Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett R, Nasser S, Ravenberg L, White J, Clayborn A, Guerra G, Litton JK, Damodaran S, Layman R, Valero V, Tripathy D, Lewis M, Dobrolecki LE, Lei J, Candelaria R, Arun B, Rauch G, Zhao L, Zhang J, Ding Q, Symmans WF, Chang JT, Thompson AM, Moulder SL, Ueno NT.
Lim B, et al.
Cell Rep Med. 2024 Jun 18;5(6):101595. doi: 10.1016/j.xcrm.2024.101595. Epub 2024 Jun 4.
Cell Rep Med. 2024.
PMID: 38838676
Free PMC article.
Clinical Trial.